Cell Therapeutics, Inc. (NASDAQ:CTIC) recently traded higher than its average volume. CTIC was opened at $0.43 increased +0.025 points or +5.75%. CTIC transacted shares during the day were over 31.98 million shares however it has an average volume of 4.86 million shares.
CTIC has an operating margin of -23434.17% and its profit margin remained -25967.40% for the last 12 months. The company has earnings of-147.56 million and made $ 0.32 million revenue for the last 12 month. Its quarter to quarter earnings per share (EPS) remained 6.44%.
The company has 900.80 million of outstanding shares and 887.49 million shares were floated in the market. According to the most recent quarter its current ratio was 0.66 that represents company’s ability to meet its current financial obligations.
The price moved ahead of 54.10% from the mean of 20 days, 37.40% from 50 and went up 22.36% from 200 days average price. Company’s performance for the week was 53.33%, 39.39% for month and yearly performance remained -28.12%.
Cell Therapeutics, Inc., a biopharmaceutical company, engages in the development, acquisition, and commercialization of drugs for the treatment of cancer. The company is developing Pixuvri, a novel anthracycline derivative for the treatment of non-Hodgkins lymphoma, as well as for various other hematologic malignancies and solid tumors; OPAXIO, a Phase III clinical trial product for the treatment of ovarian, brain, esophageal, and non-small cell lung cancer; and Brostallicin, a phase II trial for the treatment of metastatic triple-negative breast cancer. It is also developing Bisplatinates, a platinum-based chemotherapy drug to treat various kinds of cancers. The company has collaboration and licensing agreements with PG-TXL Company, L.P.; Gynecologic Oncology Group; Nerviano Medical Sciences; Cephalon; and Novartis. Cell Therapeutics, Inc. was founded in 1991 and is based in Seattle, Washington
